Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UBS5
UPID:
GABR1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UBS5; B0UXY7; O95375; O95468; O95975; O96022; Q5STL4; Q5SUJ8; Q5SUL3; Q71SG6; Q86W60; Q9UQQ0
Background:
Gamma-aminobutyric acid type B receptor subunit 1 (GABBR1) is a pivotal component of the GABA receptor, a heterodimeric G-protein coupled receptor essential for neurotransmission. GABBR1, in partnership with GABBR2, mediates the inhibitory effects of GABA by regulating various downstream effectors, including adenylate cyclase and potassium channels. This regulation is crucial for maintaining synaptic transmission, influencing neuronal excitability, and modulating neurotransmitter release.
Therapeutic significance:
Understanding the role of Gamma-aminobutyric acid type B receptor subunit 1 could open doors to potential therapeutic strategies. Its involvement in synaptic inhibition, long-term potentiation, and antinociception highlights its potential as a target for treating neurological disorders.